Long-term immunological responses to treatment among HIV-2 patients in Côte d’Ivoire
Open Access
- 12 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Infectious Diseases
- Vol. 20 (1), 1-7
- https://doi.org/10.1186/s12879-020-4927-x
Abstract
Studies indicate that responses to HIV-2 treatment regimens are worse than responses to HIV-1 regimens during the first 12 months of treatment, but longer-term treatment responses are poorly described. We utilized data from Côte d’Ivoire’s RETRO-CI laboratory to examine long-term responses to HIV-2 treatment. Adult (≥15 years) patients with baseline CD4 counts < 500 cells/μl that initiated treatment at one of two HIV treatment centers in Abidjan, Côte d’Ivoire between 1998 and 2004 were included in this retrospective cohort study. Patients were stratified by baseline CD4 counts and survival analyses were employed to examine the relationship between HIV type and time to achieving CD4 ≥ 500 cells/μl during follow up. Among 3487 patients, median follow-up time was 4 years and 57% had documented ART regimens for > 75% of their recorded visits. Kaplan-Meier estimates for achievement of CD4 ≥ 500 cells/μl after 6 years of follow-up for patients in the lower CD4 strata (< 200 cells/μl) were 40% (HIV-1), 31% (HIV-dual), and 17% (HIV-2) (log-rank p < 0.001). Cox Regression indicated that HIV-1 was significantly associated with achievement of CD4 ≥ 500 cells/μl during follow-up, compared to HIV-2. Sub-optimal responses to long-term HIV-2 treatment underscore the need for more research into improved and/or new treatment options for patients with HIV-2. In many West African countries, effective treatment of both HIV-1 and HIV-2 will be essential in the effort to reach epidemic control.Funding Information
- U.S. President’s Emergency Plan for AIDS Relief (none)
This publication has 34 references indexed in Scilit:
- CD4 Cell Count and the Risk of AIDS or Death in HIV-Infected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHEREPLoS Medicine, 2012
- Virological Response to Highly Active Antiretroviral Therapy in Patients Infected with Human Immunodeficiency Virus Type 2 (HIV-2) and in Patients Dually Infected with HIV-1 and HIV-2 in The Gambia and Emergence of Drug-Resistant VariantsJournal of Clinical Microbiology, 2009
- Rapid scaling-up of antiretroviral therapy in 10 000 adults in Côte d'Ivoire: 2-year outcomes and determinantsAIDS, 2008
- In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease InhibitorsAntimicrobial Agents and Chemotherapy, 2008
- Direct Evidence of Lower Viral Replication Rates In Vivo in Human Immunodeficiency Virus Type 2 (HIV-2) Infection than in HIV-1 InfectionJournal of Virology, 2007
- CD4+ Cell Count 6 Years after Commencement of Highly Active Antiretroviral Therapy in Persons with Sustained Virologic SuppressionClinical Infectious Diseases, 2007
- Factors Influencing Increases in CD4 Cell Counts of HIV?Positive Persons Receiving Long?Term Highly Active Antiretroviral TherapyThe Journal of Infectious Diseases, 2004
- Antiretroviral therapy in HIV-2-infected patientsAIDS, 2003
- Reduced Rate of Disease Development After HIV-2 Infection as Compared to HIV-1Science, 1994
- A comparison of HIV-1 and HIV-2 infections in hospitalized patients in Abidjan, Côte dʼlvoireAIDS, 1990